Cosette Pharmaceuticals

President and CEO Apurva Saraf leads corporate and acquisition strategy. Cosette is backed by private equity sponsors Avista Capital Partners and Hamilton Lane, who exercise governance through the board. Day-to-day deal origination, negotiation, and integration are led by Saraf and his management team.

Cosette sources deals by monitoring divestiture pipelines at large global pharmaceutical companies. As those companies narrow their focus to high-growth patented drugs, Cosette evaluates mature, cash-flow-positive products that no longer align with the seller's strategic priorities. The firm also engages with specialty pharma companies seeking to offload non-core assets.

Neither. Cosette is an operating company backed by private equity sponsors. It manufactures and markets pharmaceutical products while pursuing acquisitions of additional legacy drug assets. There is no evidence it manages third-party capital or operates as a family office.

Cosette targets mature, FDA-approved pharmaceutical products—primarily branded generics and specialty topicals. The firm acquires product rights, manufacturing lines, and entire portfolios from sellers simplifying their operations. It does not invest in early-stage biotech, pre-revenue drug development, or venture-stage therapeutics.

Yes. Cosette operates at least one US-based manufacturing facility, which produces both its proprietary products and contract manufacturing for other firms. Owning manufacturing gives Cosette control over supply chain and quality, a structural advantage when integrating newly acquired products.